This article is more than 5 years old. Information may no longer be current.

Bicycle Therapeutics, ThromboGenics advance study of DME treatment

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Bicycle Therapeutics has received a milestone payment in connection with initiation of a clinical study evaluating THR-149 for the treatment of diabetic macular edema.

The phase 1 open-label, multicenter, dose escalation study will proceed under the biotechnology company’s ophthalmology alliance with the biopharmaceutical company ThromboGenics.

The two companies are expanding their collaboration to further identify and optimize bicyclic peptide products for treating ophthalmic diseases, according to a press release from Bicycle Therapeutics.

THR-149 is a plasma kallikrein inhibitor that is being developed with the Bicycle bicyclic peptide platform and is intended for intravitreal administration. The trial will evaluate the safety of the treatment, and results are anticipated by mid-2019, according to the release.